ID

14959

Beschrijving

Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01444716

Link

https://clinicaltrials.gov/show/NCT01444716

Trefwoorden

  1. 09-05-16 09-05-16 -
Geüploaded op

9 mei 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Advanced Cancers NCT01444716

Eligibility Advanced Cancers NCT01444716

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
Beschrijving

chronic lymphocytic leukemia

Datatype

boolean

Alias
UMLS CUI [1]
C0023434
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
Beschrijving

ecog

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
Beschrijving

adequate renal and hepatic function

Datatype

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0232741
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
Beschrijving

prolymphocytic leukemia

Datatype

boolean

Alias
UMLS CUI [1]
C0023486
known positivity for hiv
Beschrijving

hiv

Datatype

boolean

Alias
UMLS CUI [1]
C0019682
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
Beschrijving

hepatitis b

Datatype

boolean

Alias
UMLS CUI [1]
C0019163
prior treatment for chronic lymphocytic leukemia
Beschrijving

chronic lymphocytic leukemia

Datatype

boolean

Alias
UMLS CUI [1,1]
C0023434
UMLS CUI [1,2]
C1514463
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
Beschrijving

concurrent chemotherapy

Datatype

boolean

Alias
UMLS CUI [1]
C3178775
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
Beschrijving

Protocol Compliance

Datatype

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
any known hypersensitivity to ofatumumab or its components.
Beschrijving

any known hypersensitivity to ofatumumab or its components.

Datatype

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1832027

Similar models

Eligibility Advanced Cancers NCT01444716

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
chronic lymphocytic leukemia
Item
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
boolean
C0023434 (UMLS CUI [1])
ecog
Item
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
boolean
C1520224 (UMLS CUI [1])
adequate renal and hepatic function
Item
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
boolean
C0232804 (UMLS CUI [1,1])
C0232741 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
prolymphocytic leukemia
Item
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
boolean
C0023486 (UMLS CUI [1])
hiv
Item
known positivity for hiv
boolean
C0019682 (UMLS CUI [1])
hepatitis b
Item
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
boolean
C0019163 (UMLS CUI [1])
chronic lymphocytic leukemia
Item
prior treatment for chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
concurrent chemotherapy
Item
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
boolean
C3178775 (UMLS CUI [1])
Protocol Compliance
Item
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
any known hypersensitivity to ofatumumab or its components.
Item
any known hypersensitivity to ofatumumab or its components.
boolean
C0020517 (UMLS CUI [1,1])
C1832027 (UMLS CUI [1,2])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial